All posts from in,

Merck: Other Human Health Franchise and Animal Health Segment

An Investor’s Guide to Merck & Co.'s Earnings in 2Q15

(Continued from Prior Part)

Other human health franchise

As we discussed earlier, the global human health segment is Merck & Co.’s (MRK) core business. Apart from the franchises discussed earlier, Merck also holds blockbuster drugs in other franchise.

Immunology franchise—Remicade

Remicade is one of the top-selling drugs for the treatment of inflammatory disorders. Its revenue fell over 25% in 2Q15—compared to 2Q14. This was mainly due to the entry of generic competitors and biosimilars following the loss of exclusivity in European markets in February 2015.

Apart from Remicade, Simponi is a drug from the inflammatory franchise. Simponi recorded growth of 20% at constant currencies in...